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Abstract
Emerging viruses including Nipah, Hendra, Lujo, and Junin viruses have enormous potential to spread rapidly. Nipah virus,
after emerging as a zoonosis, has also evolved the capacity for human-to-human transmission. Most of the diseases caused
by these pathogens are untreatable and require high biocontainment conditions. Universal methods for rapidly identifying
and screening candidate antivirals are urgently needed. We have developed a modular antiviral platform strategy that relies
on simple bioinformatic and genetic information about each pathogen. Central to this platform is the use of envelope
glycoprotein cDNAs to establish multi-cycle replication systems under BSL2 conditions for viral pathogens that normally
require BSL3 and BSL4 facilities. We generated monoclonal antibodies against Nipah G by cDNA immunization in rats, and
we showed that these antibodies neutralize both Nipah and Hendra live viruses. We then used these effective Henipavirus
inhibitors to validate our screening strategy. Our proposed strategy should contribute to the response capability for
emerging infectious diseases, providing a way to initiate antiviral development immediately upon identifying novel viruses.
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Introduction
A continuous threat is posed by newly emerging and reemerging
infectious diseases, many of which are of viral origin (reviewed in
[1,2]). Over the past decade, the global effort to meet this
challenge has resulted in an enhanced ability to identify and
genetically fingerprint the causative agent, often with extraordi-
nary speed, as seen in the severe acute respiratory syndrome
(SARS) episode in 2003–2004 [3] and the H1N1 swine influenza
pandemic of 2009–2010 [4]. However, the speed at which we
acquire genetic information on the causative agents of newly
emerging infectious diseases is not matched by the speed at which
we can develop suitable treatments. The genetic information in the
episodes of SARS could not be translated into an equally rapid
development of new therapies, since drug discovery, both by high-
throughput screening (HTS) and rational design, requires
information that does not easily derive from knowledge of the
viral genome. Additionally, for novel emerging viruses, the
resources required for classical drug discovery are not easily
mobilized for diseases with limited market potential and/or
sporadic outbreaks. However, these are exactly the situations
where immediate availability of a specific, easy to use and HTS
amenable system would be most valuable, since it would allow
rapid testing of potential antiviral and immune activity.
For enveloped viruses, it is possible to identify the envelope
glycoproteins directly from their genetic information, and to rapidly
produce synthetic cDNAs corresponding to key domains of the viral
fusion machinery. In this report, we outline a strategy that rapidly
and predictably transforms these cDNAs into BSL2 amenable
screening tools. We thereby identify a common screening platform
applicable to multiple pathogens where the salient information
(envelope glycoprotein cDNAs) can be identified by bioinformatic
analysis of the viral genome. We can then screen for antiviral
molecules that have high potency and acceptable pharmacological
properties. Using a simple protocol for developing neutralizing
antibodies and/or DNA vaccination, we validate the screening
strategy and show that it can be used to screen for neutralizing
antibodies from infected populations.
Nipah (NiV) and Hendra (HeV) viruses are two closely related,
recently emerged, causative agents of zoonosis, capable of causing
significant mortality in humans and animals [5,6,7]. Since their
emergence (NiV in 1998 and HeV in 1994), both viruses have
re-emerged several times with recent outbreaks showing, in the
case of Nipah, well documented person-to-person transmission
PLoS ONE | www.plosone.org 1 March 2012 | Volume 7 | Issue 3 | e30538[8,9,10]. Almost every year since 2001, the virus has flared up in
Bangladesh, killing 111 people in the last decade [1,7,11,12].
There are no vaccines available for either virus, although both
protein [13,14] and DNA [15] vaccination approaches appear to
be potentially effective. The alternative of passive immunotherapy
has been shown to be effective in cat, hamster, and recently, ferret
models of disease [14,16,17,18]. However, both NiV and HeV are
BSL4 agents, limiting the rapid development of antibodies and
making large scale screening of antiviral compounds difficult [19].
The generation of monoclonal antibodies using cDNA immu-
nization is highly valuable for rapid development of immunization
strategies against a broad range of viruses, particularly in the case
of new and emerging viruses. We show here that cDNA obtained
from viral genomic information is sufficient to immunize animals
and that this immunization elicits antibodies that are effective
against live viruses. The cDNA can also be prepared directly from
sequence and bioinformatic information about the viral glycopro-
teins, offering a quick route to passive immunization.
Key to the utility of the screening approach that we describe
here is the use of the genes that encode envelope glycoproteins
derived from a target virus to quickly assess potential antivirals.
We transfect cells with plasmids that encode the target virus’
envelope glycoproteins, and then infected the cells with vesicular
stomatitis virus (VSV) lacking the gene for the entry glycoprotein
G, but pseudotyped with VSV G. In this system we observed
multi-cycle replication (MCR) of the target virus iedn the
transfected cells [20]. We subsequently assessed antiviral agents
for their ability to inhibit viral spread. This method has several
advantages. It can be performed safely under BSL2 conditions,
there is no need to produce pseudotyped viruses for each new
emerging virus, and quantitative results can be obtained within
72 hours. We have successfully established this platform and
demonstrated multi-cycle replication under BSL2 conditions for
the 1918 influenza virus, a BSL3 pathogen, in addition to 3 BSL4
pathogens, Junin virus, NiV and the recently described Lujo virus
[21], as proof of concept. The principle can be applied very easily
to other viruses. We previously described a similar assay, that
mimicked multicycle replication for HeV [20]. The new assay
reported here however does not require a specific pseudotype to be
produced for the primary infection, and hence will reduce the time
required to set up an assay method tailored to each new emerging
virus. The pseudotyped virions bearing the VSV-G required for
the primary infection can be prepared in advance and in high titer.
This will allow rapid screening of possible antiviral agents
including antibodies, carried out in cells that reflect the natural
host tissue. In addition, the screening assay can be adapted for
immunological diagnostic analysis.
We envisage this pseudotyped MCR assay as a platform
technology that will enable the preparation and storage of a
specific sets of assay reagents for a wide range of viral pathogens,
at low cost, in advance of any actual outbreak of the corresponding
viral disease. This could form the basis for an efficacious and
timely outbreak response, immediately following the identification
of dangerous new viruses.
Results
A new multicycle viral replication assay enables
assessment of high-risk viral pathogens under BSL2
conditions
The multicycle replication assay that we described previously
[20] as well as other BSL2 amenable assays [22,23,24], require
production of pseudotyped stocks specific for each new emerging
virus. This significantly adds to the time required to establish an
assay for each new virus. In order to facilitate more universal
application of this technology, we have established a simple system
for multiple viruses that can be used for evaluating antivirals and
antibody efficacy. We modified the original assay by using only a
single pseudotyped virus for infection. The pseudotyped virus used
in this system is prepared with a VSV background, using VSV
delta G pseudotyped with VSV G. This enables virus entry
mediated by VSV G, but does not result in subsequent rounds of
infection by VSV. By supplying the envelope glycoproteins of the
‘‘new’’ virus in trans, the resulting virus production and release is
of a pseudotyped ‘‘new’’ virus, which mimics native virus in terms
of infection, replication and release (see Fig. 1). To test this
concept, 293 T cells were transfected with plasmids encoding the
surface glycoproteins of NiV (G/F), concomitantly with YFP
(yellow fluorescent protein) to allow visualization of the transfec-
tion. Transfected cells were then either infected with pseudotyped
VSV-DG carrying RFP (allowing visualization of infected cells) or
left uninfected. A set of control wells with cells transfected with a
control plasmid were also infected with the pseudotyped virus. The
virus underwent multicycle replication in transfected cells as
Figure 1. Modified multicycle viral replication assay. When VSV G pseudotyped viruses infect viral glycoprotein (G/F)-expressing permissive
cells, multicycle replication is simulated where the initial entry is by VSV G pseudotyped virus but subsequent replication cycles are those of NiV
pseudotyped virus produced after budding.
doi:10.1371/journal.pone.0030538.g001
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infection (Fig. 2). Even though the initial infection event is
mediated by VSV pseudotyped virus, the second, and subsequent,
rounds will be those of NiV due to the expression of the transfected
glycoproteins (G/F). For high-throughput screening (HTS) a
universal measure of assay quality and robustness, is the Z value. A
Z9 value 1.0 is considered to be perfect, and assays with a value
above 0.5 are required. The Z9 value for the multicycle replication
as compared to the uninfected control was 0.83 (table 1), rendering
it amenable to HTS.
cDNA immunization of rabbits to generate polyclonal
antibodies and inhibition of infection in the unmodified
MCR assay
In parallel, we tested whether cDNA immunization would
generate antibodies with high neutralizing activity and specificity.
Rabbits were immunized with pCAGGS-HeV F or pCAGGS-HeV
G. Serum was collected from the immunized animals and tested in
the original (16) MCR assay format. Briefly, 293 T cells transfected
with NiV F/G concomitantly with Venus-YFP were infected with
pseudotyped NiV and infection was measured 48 hrs post infection
by reading the intensity of RFP expression. Polyclonal antibodies
from all 4 rabbits inhibited infection in our original pseudotyped
viral entry assay format using NiV pseudotyped VSV (Fig. 3A). A
small amount of cell-cell fusion can be seen in the presence of anti-
HeV G antibodies while the anti-HeV F antibodies completely
inhibit fusion. However, the anti-HeV G antibodies, especially from
rabbit D, gave a better dose response than anti-HeV F antibodies
(Fig. 3B).
cDNA immunization of rats and evaluation of in-vitro
neutralizing activity of anti-NiV G polyclonal and
monoclonal antibodies using the new multicycle
pseudotyped virus assay
To test the universality of this approach, we immunized rats
with cDNA to generate antibodies against NiV G. Five rats were
immunized with pCAGGS-NiV G. As the first step, serum from
five rats were collected and tested for inhibition of infection in the
modified MCR assay. Infection was measured 48 hrs after
infection. Polyclonal antibodies from three rats had relatively
low titers of neutralizing activity. Polyclonal antibodies from Rat 2
and Rat 4 had much stronger neutralizing properties (Fig. 4A),
showing greater inhibition at higher dilutions than Rats 1, 3 and 5.
Monoclonal antibodies were also generated by immunizing rats
with pCAGGS-NiV G, and tested in the MCR assay. At a
concentration of 0.044 mg/ml, all monoclonal antibodies show
70%–80% inhibition of infection (Fig. 4B). However at a lower
concentration of 0.009 mg/ml, only antibody 1 inhibits 60% of
infection. Antibodies 2, 3 and 4 are able to inhibit only ,40% of
infection. The monoclonal antibodies were specific for NiV G by
FACS analysis (data not shown).
Validation of the cDNA-derived antibodies with authentic
viruses
We considered the possibility that the cDNA immunization
strategy may elicit antibodies that do not neutralize live viruses.
The conformation of the proteins produced by the cDNA could be
significantly different from that on the viral particles, resulting in
induction of antibodies whose specificity could be significantly
different from that induced during viral infection. For example,
immunization with high concentrations of Ebola GP did not
induce neutralizing antibodies [25]. In contrast, immunization
with VLPs or VSV/Ebola GP chimeric virus induced neutralizing
antibodies [26,27]. To validate our strategy for live Nipah and
Hendra viruses we performed a in vitro neutralization assay
(Table 2). The neutralizing capacity of the polyclonal rabbit and
monoclonal rat antibodies that we generated was compared to that
of the murine mAb anti-NiV F, Gip21, previously reported to
neutralize both NiV and HeV [18]. Although rabbit polyclonal
anti-HeV G sera did not exhibit neutralizing capacity at the
dilutions tested, both rabbit polyclonal anti-HeV F antibodies
neutralized HeV, and one of these neutralized NiV infection as
well. All rat monoclonal anti-NiV G antibodies inhibited NiV
infection, and one of them neutralized HeV as well. Together,
these results demonstrated that the immunization strategy applied
in this study allows for generation of anti-viral polyclonal and
monoclonal antibodies that neutralize live viruses.
Validation of the new pseudotyped virus assay
To validate our modified pseudotyped virus assay, we compared
the results of two rat polyclonal antibodies raised against NiV G
using the assay described above and our modified MCR assay.
These antibodies inhibited both the multicycle replication of NiV
pseudotyped virus –the unmodified version of the multicycle
replication assay, which uses the NiV pseudotype for infection
(Fig. 5A)– and our newly modified assay described above using
pseudotyped VSV for entry (Fig. 5B). However the effectiveness in
Figure 2. NiV multicycle replication using modified assay. Cells
were transfected with plasmids encoding NiV G and F (triangles) and
then infected with pseudotyped VSV. Transfected cells were also left
uninfected as a control (squares). Additionally, control cells transfected
with empty plasmid were also infected with pseudotyped VSV, showing
single cycle replication (circles). Relative fluorescent intensities of the
RFP were measured after 24, 48, 72 and 96 hours.
doi:10.1371/journal.pone.0030538.g002
Table 1. Z9 values of multicycle replication compared to no
infection control using VSV pseudotype at 72 hours post
infection.
Virus Z9 value
Influenza 0.78
Junin 0.51
Lujo 0.84
NiV 0.72
VSV 0.83
doi:10.1371/journal.pone.0030538.t001
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obtained when pseudotyped NiV was used for infection. For viral
fusion inhibitors, we found that efficacy at inhibiting viral entry
does not necessarily correlate with in vivo protection, while the
ability of an inhibitor to block the spread of virus through a
monolayer of cells after infection correlates positively with in vivo
efficacy [28,29]. Thus, this platform allows not only quick
screening of antivirals, it may also help to accurately estimate
the effectiveness of these compounds. Importantly, and perhaps
explaining the apparently lower antiviral efficacy in the newly
modified assay, this assay accounts for the context of viral spread,
as distinct from merely the entry event. The ability to curtail
multicycle replication even after infection has occurred is likely to
provide an important advantage in the success of antiviral therapy.
The modified MCR assay is adaptable to other enveloped
viruses
Once the assay was established, we investigated the application
of this system to other viruses. For this purpose, 293 T cells were
transfected with plasmids encoding the surface glycoproteins of
Lujo virus (Fig. 6A), Junin virus (Fig. 6B) or VSV (Fig. 6C)
concomitantly with YFP (yellow fluorescent protein) to allow
visualization of the transfection. Transfected cells were then either
infected with pseudotyped VSV-DG carrying RFP (allowing
visualization of infected cells) or left uninfected. As an additional
control, cells transfected with the control plasmid were also
infected with the pseudotyped virus (single cycle). All the viruses
underwent multicycle replication in cells transfected with the
cDNA of the viral glycoprotein(s) as indicated by an increase in
RFP expression over time post infection (Fig. 6). We observed
minimal differences in RFP expression between cells during the
initial round of infection (as expected) but as the length of
incubation increased, and subsequent rounds of infection occurred
in the multi-cycle system, RFP expression became 2–4 fold higher
in transfected cells at 72 and 96 hours, respectively. This reveals a
rapidly adaptible system that permits assessment of viral infection
and antiviral efficacy for any enveloped virus. The Z9 values for
the multicycle replication as compared to the uninfected controls
Figure 3. Multicycle replication (MCR) inhibition by antibody neutralization. (A) Cells coexpressing Nipah G/F and Venus-YFP were infected
with pseudotyped VSV-DG-RFP-Nipah F/G, in the presence of anti-F or anti-G rabbit polyclonal antibodies. 48 hrs post-infection, the relative
fluorescence intensities (RFI) were measured (B) and the spectral emission from the cells was converted into photographs (A). The bottom panel of
photographs show extensive fusion in cells in the absence of antibodies (control), while no fusion is observed in the cells treated with anti-F
antibodies, and some fusion is observed in the presence of anti-G antibodies. (B) polyclonal antibodies specific for HeV F or HeV G inhibit NiV
pseudotype infection. Anti-HeV G antibodies show better dose response than anti-HeV F antibodies.
doi:10.1371/journal.pone.0030538.g003
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plate format and showed very small deviations over large number
of replicates.
To confirm that the modified assay(s) were useful, and specific
for antiviral efficacy evaluation, we tested chloroquine (data not
shown) – which we had previously shown to inhibit henipavirus
multicycle replication –against the viruses in the MCR assay [20].
Chloroquine showed very high antiviral activity against NiV but
very little activity against the other viruses at concentrations lower
than 20 mM. When chloroquine was used at 100 mM it effectively
blocked the VSV MCR assay as expected [30]. Note that
chloroquine is a positive control for the cell based assay and it is
not intended as a comparison for in vivo efficacy.
In addition to its utility for novel emerging viruses, this modified
assay format can be applied to highly pathogenic influenza viruses
that require a BSL3 facility. We adapted our MCR assay to
evaluate replication of the 1918 influenza virus. We observed
multicycle replication for this virus using TPCK treated trypsin
treatment with neuraminidase treatment in the modified assay
Figure 4. Inhibition of Multicycle replication by neutralizing
antibodies. (A) Polyclonal antibodies were raised against NiV G in rats.
While all the antibodies show inhibition of infection, the polyclonal
antibodies from Rat #2 and Rat #4 show the strongest effect. (B) Anti-
NiV monoclonal antibodies block NiV G/F in the MCR assay.
doi:10.1371/journal.pone.0030538.g004
Table 2. Antibody-mediated neutralization of live Nipah and
Hendra viruses.
Antibody Titer (NiV)* Titer (HeV)*
Polyclonal anti-HeV G (rabbit #C) ,50 ,50
Polyclonal anti-HeV G (rabbit #D) ,50 ,50
Polyclonal anti-HeV F (rabbit #A) 800 1200
Polyclonal anti-HeV F (rabbit #B) ,50 300
mAb anti-NiV G (rat hybridoma 2) 600 ,50
mAb anti-NiV G (rat hybridoma 1) 11400 200
mAb anti-NiV G (rat hybridoma 4) 2400 ,50
Murine mAb anti-NiV F GIP21** 300 600
*Relative neutralization titer is presented as a reciprocal dilution of antibody
samples that completely inhibited either NiV or HeV cytopathic effect.
**Control antibody [18].
doi:10.1371/journal.pone.0030538.t002
Figure 5. Validation of modified pseudotype assay validation
for NiV. Cells were transfected with plasmids encoding the NiV
glycoproteins F and G and then infected with either pseudotyped NiV
(A) or pseudotyped VSV (B) in presence of rat anti-NiV antibodies, Rat 2
(circles) or Rat 5 (squares). Relative fluorescent intensities of the RFP
were measured after 48 hrs.
doi:10.1371/journal.pone.0030538.g005
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the uninfected control was 0.78.
Discussion
Passive immunotherapy addresses the problem of quickly
treating or protecting large populations of people against possible
exposure to a virus, especially in the absence of a vaccine. Passive
immunization is ideal for cases where the probability of exposure
to infection is low or the causative agent is unidentified. However,
quick generation of antibodies is key to an effective immunization
plan, particularly in the case of emerging viruses. One problem
that hinders the development of passive immunotherapy is the
effective generation of antibodies. Traditionally, antibodies have
been raised against either the dead/attenuated form of the
causative agent, or against the entire or a subunit of a protein
involved in the infection [13]. However, this method suffers from
problems of purity and amount, though a high level of immunity is
usually generated. cDNA immunization avoids the above
problems since the viral glycoproteins are expressed on the cell
surface in the animal, allowing the antibodies to be raised against
the native form of the protein and thus to attain high activity and
specificity [31,32,33]. This method is particularly suited for the
generation of antibodies against membrane proteins. We show
here that cDNA immunization of rats using cDNA corresponding
to the surface glycoproteins of viruses, (NiV in our example),
effectively generates monoclonal antibodies whose activity and
specificity can be tested using a platform adaptable to a broad
range of viruses.
An important advantage of the cDNA immunization method is
that it rests on the sequence information of the viral genome, as in
the case of envelope glycoproteins of unidentified infections,
including zoonoses that have recently adapted to infection of
humans. Often, transport of the infectious agent is not possible,
limiting the development of antibodies, since the resources required
for antibody generation may not be close to the site of viral
detection. This can be especially true of emerging diseases, as
highlighted by repeated NiV re-emergence in rural Bangladesh
[34]. In these cases, cDNA immunization offers a fast and effective
way to generate antibodies with specific neutralizing activity for the
virus under investigation. Our results indicate that the antibodies
raised by cDNA immunization neutralized live virus. Interestingly,
severalof the anti-F antibodies raised against Hendra F also blocked
Nipah infection. While all the monoclonal anti-NiV G mAbs
neutralized NiV, just one of them exhibited significant cross-
neutralization against Hendra virus. Our data taken together with
Figure 6. The modified assay can be adapted to other viruses. Cells were transfected with plasmids encoding glycoproteins from Lujo (A),
Junin (B), VSV (C) or the influenza glycoprotein HA (D) then infected with pseudotyped VSV (triangles). Transfected cells were also left uninfected asa
control (squares). Additionally, cells transfected with control empty plasmid were also infected with pseudotyped VSV showing single cycle
replication (circles). Relative fluorescent intensities of the RFP were measured after 24, 48, 72 and 96 hours.
doi:10.1371/journal.pone.0030538.g006
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eliciting anti-F antibodies, at least for the cDNA immunization,
may lead to more broadly neutralizing antibodies [18].
The use of passive immunotherapy has the advantage of
generating immunity immediately in the patient. However,
evaluating the neutralizing activity of potential therapeutic
antibodies requires infection of cells with the virus of interest.
This is a limiting problem in antibody generation when the virus is
a BSL4 pathogen like NiV and HeV, or where there are difficulties
associated with transportation of the virus from the point of
detection to a suitable laboratory. The assay that we describe
overcomes these problems by using pseudotyped viruses to infect
cells that express glycoproteins of the same virus. Thus, the
neutralizing activity of the antibody can be analyzed and evaluated
using an assay that simulates multi-cycle replication of a virus
under BSL2 conditions. This not only increases the speed of the
development of effective antibody protection, it also significantly
reduces testing costs. The MCR assay distinguishes between
antibodies of differing neutralizing activity and specificity and
replicates the antiviral selectivity seen with live viruses. Antibodies
showing high inhibition at only low dilutions may be doing so due
to non-specific interactions with the surface glycoproteins, while
weak antibodies show low levels of infection inhibition.
One hurdle that we have not addressed in the current study
relates to the possibility that monoclonal antibodies developed
using cDNA immunization of rats have an associated risk of
invoking an immune response and human anti-rat antibodies.
Such events negate the intended therapeutic effect of the antibody.
Fortunately, the task of humanization to arrive at products that are
not recognized as antigens in the recipient is now relatively straight
forward. In the next phase of this research, we plan to use cDNA
immunization of mice genetically modified to produce humanized
antibodies. A human monoclonal antibody against Nipah G has
shown partial protection in the ferret animal model [16]. The
antibody was identified by screening a human Fab library and
soluble G protein [35]. The strategy described in this manuscript
would allow for the direct identification of neutralizing human
monoclonal antibodies, without intermediate steps.
We propose that the system we describe could be designed as a
kit that includes the genetic material for the VSV-DG-RFP [36],
ultimately requiring only the specific viral cDNA to be mixed
together with the transfection mixture just before addition to the
cells. A cost effective transfection reagent would be a major
advantage for such a kit, and therefore we adapted our assay to use
PEI [37] for transfection, bringing down the cost of the
transfection reagent by several fold and rendering the system
feasible at very low budget. The system that we propose has some
limitations. We can screen only for antivirals that target entry, and
not other steps in the viral life cycle, and we require viral envelope
proteins that are compatible with VSV.
In summary, we propose a novel platform for screening of
antiviral compounds and antibodies against newly emerging
viruses. This assay can be established rapidly using just the
sequence information of new and emerging viruses. The assay is
highly reproducible and sensitive and can be performed in a BSL2
facility, providing a safe method for potentially highly pathogenic
newly emerging viruses that otherwise require BSL3 or BSL4
containment facilities. The assay behaves consistently at low cell
numbers, and thus allows miniaturization to a 384 well format,
making it amenable to high-throughput screening. This concept
can also be easily applied to primary cells, which may reveal
different antiviral potencies from those in laboratory adapted
monolayers [28,29]. If used in comparison with the unmodified
multicycle replication assay, this strategy also reveals differences
between agents that inhibit entry, and agents that inhibit tissue
spread of viruses.
Materials and Methods
Cells and virus
293 T (human kidney epithelial) and Vero (African green
monkey kidney) cells were grown in Dulbecco’s modified Eagle’s
medium (DMEM; Mediatech-Cellgro) supplemented with 10%
fetal bovine serum and antibiotics at 37uCi n5 %C O 2.
Pseudotyped viruses were generated using VSV-DG-RFP, a
recombinant VSV derived from the cDNA of VSV Indiana in
which the G gene is replaced with the Ds-Red gene (RFP).
Pseudotypes with NiV F and G were generated as described
previously [38]. Briefly, 293 T cells were transfected with plasmid
encoding VSV-G or NiVF/G. Five hours post-transfection, the
dishes were washed and infected (multiplicity of infection [MOI]
of 0.5) with VSV-DG-RFP complemented with VSV-G. Super-
natant fluid containing pseudotyped virus (NiV F/G or VSV-G)
was collected 18 h post-infection and stored at 280uC.
NiV isolated from the cerebrospinal fluid of a patient was
received from Dr. K.B. Chua and Dr. S.K. Lam (University of
Malaya, Kuala Lumpur, Malaysia). HeV was obtained from
Graham Lloyd at the exotic virus bank at Porton Down, England.
NiV and HeV stocks were prepared by infecting Vero-E6 cells as
previously described [39], in the INSERM Jean Me ´rieux biosafety
level 4 (BSL-4) laboratory in Lyon, France.
Chemicals
Chloroquine diphosphate salt was obtained from MP Biomed-
icals (cat# 193919)
Pseudotyped entry assay mimicking multicycle
replication
As described previously [20,38], NiVF/G glycoproteins were
pseudotyped onto VSV-DG–RFP and the resulting pseudotyped
viruses were used to infect NiV F/G-expressing cells at an MOI of
0.125 for simulation of multicycle replication. RFP production at
24, 48, 72 and 96 hr was analyzed on a microplate fluorescence
reader (Spectramax M5). For detecting RFP expression levels, the
wells were read by excitation at 535-nm and emission at 579-nm.
For the detection of YFP expression, the wells were read by
excitation at 510-nm and emission at 535-nm. For the modified
multicycle replication assay, VSV G glycoprotein was pseudotyped
onto VSV-DG–RFP and the resulting pseudotyped viruses were
used toinfectviralglycoprotein(s)-expressing cells fora simulation of
multicycle replication. For single-cycle infection assays, the VSV-G
pseudotype was used at an MOI of 0.125 to infect 293 T cells
transfected with control plasmid. For Influenza virus, 2.5 ug/ml of
TPCK trypsin and 0.001 mu neuraminidasewasadded to thewells.
Antibodies
Polyclonal antibodies were raised in rabbits (anti-HeV F or anti-
HeV G) or rats (Anti-NiVG) by cDNA immunization with
plasmids expressing either HeV G, HeV F or NiV G using
standard, commercailly available, protocols (Genovac). Monoclo-
nal antibodies were produced using proprietary protocols by
Genovac, using the NiV G cDNA. Isotype of the mAbs used in this
study was IgG2b.
Virus neutralization assay
NiV and HeV neutralizing antibodies were tested using two-fold
dilutions of samples as described previously [18].Diluted antibod-
BSL2 Multi-Cycle Assay for Emerging Viruses
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plates) for 60 min at 37uC in DMEM (Gibco) supplemented with
2% FCS. A total of 2.5610
4 Vero cells were then added to each
well as indicator cells, and 96-well plates were incubated for 4 days
at 37uC. Relative neutralizing titers were defined as the reciprocal
dilution of antibody samples that completely inhibited the
cytopathic effect of either NiV or HeV.
Plasmids and reagents
The genes encoding influenza HA 1918, Nipah G and F were
commercially synthesized and then cloned into pCAGGS vector.
Junin and Lujo GPC in pCAGGS from Dr. Thomas Briese.
Testing of anti-NiV G antibodies
293 T cells were transfected with plasmids encoding NiV G/F
and YFP. Four hours post- transfection, antibodies were added at
the indicated dilutions and then the cells were infected with VSV-
G pseudotyped virus or with NiV F/G pseudotyped virus at an
MOI of 0.125.
Data Processing and Normalization
The Z9 values were used an assessment of quality [40], using the
16 values of the inhibitor and the blank for each microtiter plate as
follows:12(3*St.dev. inhibitor+3*St.dev. blank)/|Average inhibi-
tor2Average blank|
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